艾拉司群的專利技術(shù)分析

打開(kāi)文本圖片集

中圖分類號(hào)：R979.1 文獻(xiàn)標(biāo)志碼：A 文章編號(hào)：1003-5168（2025）07-0132-06

DOI：10.19968/j.cnki.hnkj.1003-5168.2025.07.026

Abstract： [Purposes] Based on patent information，this study aims to analyze the development history of Elacestrant，the world's first orally available selective estrogen receptor degrader （SERD）approved for market，assisting researchers in understanding the drug's development process，trends，and intellectual property protection in China.It also provides suggestions on technological development and intellectual property strategy for domestic pharmaceutical companies.[Methods] Patent literature related to Elacestrant was searched in the Himmpat and STN databases.After merging family patents，deduplication，and manual indexing to remove noise，48 valid patent documents were obtained.The analysis was conducted from the perspectives of pharmaceutical use，crystal forms， preparation methods，and combination therapies.[Findings] The original compound patent of Elacestrant，as the basic patent， was not applied for protection in China.The compound crystal forms，pharmaceutical uses，and combination therapies of Elacestrant are the focus of Radius Health's patent layout in China.[Conclusions] Radius Health has actively implemented patent layout in China from the perspectives of compound crystal forms，pharmaceutical uses，and combination therapies，achieving efective results.In contrast， domestic innovators mainly focus on the synthesis methods of Elacestrant and its important intermediates，with relatively less research on new pharmaceutical uses，drug formulations，and combination therapies of Elacestrant. Keywords：Elacestrant; oral SERD; breast cancer; patent analysis

0 引言

根據(jù)美國(guó)癌癥協(xié)會(huì)最新發(fā)布數(shù)據(jù)，乳腺癌是美國(guó)女性癌癥死亡的第2大原因，僅次于肺癌；我國(guó)國(guó)家癌癥中心在期刊JournaloftheNationalCancerCenter最新發(fā)布的數(shù)據(jù)顯示，在中國(guó)女性前10位惡性腫瘤死亡率排行中，乳腺癌排名第 。（剩余8810字）